Thomas F. Baumert
University of Strasbourg
363 Papers
1.9K Citations
Thomas F. Baumert is an academic researcher from University of Strasbourg. The author has contributed to research in topics: Hepatitis C virus & Virus. The author has an hindex of 66, co-authored 302 publications. Previous affiliations of Thomas F. Baumert include French Institute of Health and Medical Research & Harvard University.
Chat about Author
Papers
A human liver cell atlas reveals heterogeneity and epithelial progenitors.
Nadim Aizarani,Nadim Aizarani,Antonio Saviano,Antonio Saviano,Sagar,Laurent Mailly,Laurent Mailly,Sarah C. Durand,Sarah C. Durand,Josip S. Herman,Josip S. Herman,Patrick Pessaux,Patrick Pessaux,Thomas F. Baumert,Thomas F. Baumert,Dominic Grün,Dominic Grün +16 more
TL;DR: It is shown that the EPCAM+ population is heterogeneous, comprising hepatocyte-biased and cholangiocyte populations as well as a TROP2int progenitor population with strong potential to form bipotent liver organoids.
Liver Fibrosis: Mechanistic Concepts and Therapeutic Perspectives
TL;DR: In this paper, the authors summarized cellular drivers and molecular mechanisms of fibrogenesis in chronic liver diseases and discuss their impact for the development of urgently needed anti-fibrotic therapies.
826
EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy
Joachim Lupberger,Mirjam B. Zeisel,Mirjam B. Zeisel,Fei Xiao,Fei Xiao,Christine Thumann,Christine Thumann,Isabel Fofana,Isabel Fofana,Laetitia Zona,Laetitia Zona,Christopher Davis,Christopher J. Mee,Marine Turek,Marine Turek,Sebastian Gorke,Cathy Royer,Cathy Royer,Benoit Fischer,Muhammad N. Zahid,Muhammad N. Zahid,Dimitri Lavillette,Judith Fresquet,François-Loïc Cosset,S. Michael Rothenberg,Thomas Pietschmann,Arvind H. Patel,Patrick Pessaux,Michel Doffoel,Wolfgang Raffelsberger,Olivier Poch,Jane A. McKeating,Laurent Brino,Thomas F. Baumert,Thomas F. Baumert +34 more
TL;DR: Inhibition of RTK function may constitute a new approach for prevention and treatment of HCV infection and show that tyrosine kinase inhibitors have substantial antiviral activity.
742
miR-122 – A key factor and therapeutic target in liver disease
Simonetta Bandiera,Simonetta Bandiera,Sébastien Pfeffer,Sébastien Pfeffer,Thomas F. Baumert,Thomas F. Baumert,Mirjam B. Zeisel,Mirjam B. Zeisel +7 more
TL;DR: This review summarizes the current understanding of the key role of miR-122 in liver physiology and disease and discusses the perspectives of miRNA-based therapeutic approaches for viral hepatitis and liver disease.
580
Cellular Binding of Hepatitis C Virus Envelope Glycoprotein E2 Requires Cell Surface Heparan Sulfate
Heidi Barth,Christiane Schäfer,Mohammed I. Adah,Fuming Zhang,Robert J. Linhardt,Hidenao Toyoda,Akiko Kinoshita-Toyoda,Toshihiko Toida,Toin H. van Kuppevelt,Erik Depla,Fritz von Weizsäcker,Hubert E. Blum,Thomas F. Baumert +12 more
TL;DR: It is demonstrated for the first time that cellular binding of HCV envelope requires E2-HSPG interaction, and docking of E2 to cellular HSPG may be the initial step in the interaction between HCV and the cell surface resulting in receptor-mediated entry and initiation of infection.
549